Literature DB >> 16541422

Steroid sulfatase and estrogen sulfotransferase in human prostate cancer.

Yasuhiro Nakamura1, Takashi Suzuki, Tsuyoshi Fukuda, Akihiro Ito, Mareyuki Endo, Takuya Moriya, Yoichi Arai, Hironobu Sasano.   

Abstract

BACKGROUND: Estrogen sulfotransferase (EST) and steroid sulfatase (STS) are known to be involved in in situ estrogen production in estrogen dependent human cancer such as breast cancer, but unknown in prostate cancer.
MATERIALS AND METHODS: We first examined whether these enzymes above were expressed and actually involved in estrogen production and metabolism in prostate cancer cell lines (LNCaP, DU-145, and PC-3). We than examined the expression of EST and STS in human prostate cancer tissues obtained from surgery (n = 52) using immunohistochemistry.
RESULTS: mRNAs of both enzymes were detected in all prostate cancer cell lines examined, and the synthesis of estrone (E(1)) and estradiol (E(2)) was also confirmed in these cell lines. In addition, STS immunoreactivity was detected in 44 cases (85%) and EST in 39 cases (75%), respectively.
CONCLUSIONS: STS and EST are expressed and may be involved in local production and metabolism of estrogens in human prostate cancers. Copyright 2006 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16541422     DOI: 10.1002/pros.20426

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  19 in total

1.  Sex hormones and the risk of incident prostate cancer.

Authors:  Nicholas A Daniels; Carrie M Nielson; Andrew R Hoffman; Douglas C Bauer
Journal:  Urology       Date:  2010-05-07       Impact factor: 2.649

2.  Adrenal androgens rescue prostatic dihydrotestosterone production and growth of prostate cancer cells after castration.

Authors:  Yue Wu; Li Tang; Gissou Azabdaftari; Elena Pop; Gary J Smith
Journal:  Mol Cell Endocrinol       Date:  2019-02-23       Impact factor: 4.102

Review 3.  Regulation of the cytosolic sulfotransferases by nuclear receptors.

Authors:  Melissa Runge-Morris; Thomas A Kocarek; Charles N Falany
Journal:  Drug Metab Rev       Date:  2013-02       Impact factor: 4.518

4.  Induction of steroid sulfatase expression by tumor necrosis factor-α through phosphatidylinositol 3-kinase/Akt signaling pathway in PC-3 human prostate cancer cells.

Authors:  Bo Young Suh; Jin Joo Jung; Nahee Park; Cheul Hun Seong; Hee Jung Im; Yeojung Kwon; Donghak Kim; Young Jin Chun
Journal:  Exp Mol Med       Date:  2011-11-30       Impact factor: 8.718

5.  Redox regulation of human estrogen sulfotransferase (hSULT1E1).

Authors:  Smarajit Maiti; Jimei Zhang; Guangping Chen
Journal:  Biochem Pharmacol       Date:  2006-12-28       Impact factor: 5.858

Review 6.  Gene polymorphism-related differences in the outcomes of abiraterone for prostate cancer: a systematic overview.

Authors:  Min Liu; Hongzhe Shi; Jiaqing Yan; Yuan Zhang; Yinglin Ma; Kaidi Le; Zhongdong Li; Nianzeng Xing; Guohui Li
Journal:  Am J Cancer Res       Date:  2021-05-15       Impact factor: 6.166

Review 7.  Intracrine androgen metabolism in prostate cancer progression: mechanisms of castration resistance and therapeutic implications.

Authors:  Elahe A Mostaghel; Peter S Nelson
Journal:  Best Pract Res Clin Endocrinol Metab       Date:  2008-04       Impact factor: 4.690

Review 8.  Castration-resistant prostate cancer: targeting androgen metabolic pathways in recurrent disease.

Authors:  Elahe A Mostaghel; Bruce Montgomery; Peter S Nelson
Journal:  Urol Oncol       Date:  2009 May-Jun       Impact factor: 3.498

9.  Impact of Human SULT1E1 Polymorphisms on the Sulfation of 17β-Estradiol, 4-Hydroxytamoxifen, and Diethylstilbestrol by SULT1E1 Allozymes.

Authors:  Amal A El Daibani; Fatemah A Alherz; Maryam S Abunnaja; Ahsan F Bairam; Mohammed I Rasool; Katsuhisa Kurogi; Ming-Cheh Liu
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2021-01       Impact factor: 2.441

10.  Steroid Sulfatase Stimulates Intracrine Androgen Synthesis and is a Therapeutic Target for Advanced Prostate Cancer.

Authors:  Cameron M Armstrong; Chengfei Liu; Liangren Liu; Joy C Yang; Wei Lou; Ruining Zhao; Shu Ning; Alan P Lombard; Jinge Zhao; Leandro S D'Abronzo; Christopher P Evans; Pui-Kai Li; Allen C Gao
Journal:  Clin Cancer Res       Date:  2020-09-14       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.